Randy Osborne

The Medicines Co. Offering Gets $85.75M For Late-Stage Work

March 17, 2003

By Randy Osborne

Boston Life Sciences Raises $10M In Private Placement

March 14, 2003

By Randy Osborne

Vical: DNA Anthrax Vaccine Into Humans By End Of Year

March 11, 2003

By Randy Osborne

With encouraging small-animal data in hand, Vical Inc. said it will begin human testing of its anthrax DNA vaccine by the end of this year. (BioWorld Today)

Corus Raises $40M Privately For Phase II Asthma, CF Drugs

March 10, 2003

By Randy Osborne

AIDS Controversy Alive As Before; This Time, Phase III Data And Race

March 10, 2003

By Randy Osborne

Talk about a hard call.Investors may have been quick to attach their unmistakable meaning to last month's disclosure by VaxGen Inc. of disappointing Phase III results for its HIV vaccine - the company's stock value nosedived by 47.3 percent - but the scientific world was far from convinced a disaster had taken place.

ILEX Gets Non-Oncology Rights To Campath Leukemia Treatment

March 5, 2003

By Randy Osborne

Sequitur, Bristol-Myers Extend Deal To Include RNAi Research

March 4, 2003

By Randy Osborne

Deal-Making Rules Changing; Pharma, Biotechs Shop Around

March 3, 2003

By Randy Osborne

Science is all about experiments, so here's an idea for the blackboard: Imagine a world where biotechnology pays pharmaceutical companies to develop compounds.

FDA Chief Outlines Strategy; Industry Still 'Upbeat, Tough'

Feb. 28, 2003

By Randy Osborne

NEW YORK - FDA Commissioner Mark McClellan's face projected on a huge screen in the American city hit hard by terrorists on 9/11 gave him the appearance of a commander exhorting his troops, as he offered details regarding Project Bioshield. (BioWorld Today)